Spironolactone as a novel pharmacotherapy for alcohol use disorder
Closed Pre-Solicitation Posted
- Solicitation number
- 75N95020Q00334
- Agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Place of performance
- Baltimore MD 21224 USA
Notice details come from SAM.gov. Updated .
Notice text
The objective of the proposed project is to investigate the impact of spironolactone on alcohol consumption in a general patient population. Using data from the Veteran Birth Cohort, a long-term and large-scale cohort study, we will investigate the association between spironolactone use (prescribed for any indication) and alcohol consumption in adults. Spironolactone-exposed individuals will be propensity-score matched to up to five unexposed individuals. Multivariable linear regression models will estimate changes in Alcohol Use Disorders Identification Test - Consumption (AUDIT-C) scores before and after spironolactone exposure. Results will provide information on the possible early efficacy signal with this drug, building the foundation for prospective randomized clinical trials.
Please see attached Notice of Intent
Files
| File | Type | Posted |
|---|---|---|
| 6-Notice of Intent_final.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity